雷公藤红素逆转K562/A02细胞多药耐药的实验研究
|
摘要
白血病是造血系统常见的恶性肿瘤,是一组异质性起源的恶性克隆性疾病,年发病率3-4/10万。目前治疗白血病的方法主要是化疗,随着化疗方案的改进和新化疗药的出现、支持治疗的加强及干细胞移植技术的应用,白血病的治疗效果有了明显的改善。然而,多药耐药的产生则成为目前部分白血病患者不能获得缓解,或缓解后复发的主要原因。因此,寻找新的抗肿瘤药物、探索新的治疗方案具有重要的意义。
近年来,中药及其有效的成分逆转白血病多药耐药引起了人们的注意。雷公藤泛指卫矛科雷公藤属植物,是我国传统的中药材。雷公藤红素是雷公藤单体之一,是一种三萜类天然化合物,又名南蛇藤素,分子式为C29H38O4。,分子量为450。文献报道雷公藤红素有免疫抑制、抑制血管内皮细胞体外增值、抑制HMC-1细胞的黏附及其黏附分子的表达；雷公藤红素还能体外诱导非小细胞肺癌细胞株H1299、人急性髓系白血病细胞株HL-60、恶性胶质细胞瘤株、视网膜母细胞瘤等肿瘤的凋亡。本研究以人慢性粒细胞白血病急变K562细胞株和耐阿霉素K562/A02细胞株为靶细胞,采用CCK-8方法和流式细胞术,探讨雷公藤红素对K562/A02细胞的逆转作用,并检测了雷公藤红素对K562/A02细胞内ADM浓度和P-gp的表达的影响。
方法：
1、K562和K562/A02细胞的培养
K562细胞培养于含10%新生牛血清、100U/ml青霉素和1000ug/ml链霉素的RPMI-1640培养基中,K562/A02细胞培养于含阿霉素(ADM 1μmol/L)的上述培养基中,将2种细胞置于37℃、5%CO2培养箱中常规培养,2-3天传代1次,其中K562/A02细胞在实验前两周改用无阿霉素的培养基培养。取对数生长期细胞用于实验。
2、CCK-8法检测ADM、雷公藤红素的细胞毒性及耐药细胞的耐药倍数
取对数生长期细胞,采用台盼兰染色活细胞计数方法。取30 u 1细胞悬液,用台盼兰染色后镜检100个细胞并计算活细胞百分率,其中拒染细胞为活细胞,染成蓝色的细胞为死细胞。取存活率大于95%的细胞为实验细胞。将K562和K562/A02细胞(2～3×109cells/孔)于96孔板中,由高到低浓度分别加入ADM(160、80、40、20、10、5、2.5、1.25μmol/L),雷公藤红素(320、160、80、40、20、10、5、2.5μmol/L),每孔设3个复孔,终体积150 u l。在37℃、5%CO2培养箱中培养72小时后,每孔加入CCK-8试剂10μ1,继续培养2小时,以空白孔调零,在全自动酶标仪450nm处测吸光度值,参比波长650nm。所测数据采用SPSS16.0统计软件计算生长抑制率在50%的药物浓度即半数抑制率(IC50)。抑制率(%)=(1-实验组0D值/对照组OD值)×100%；耐药倍数=(耐药细胞的IC50/敏感细胞的IC50)。实验重复3次,取平均值。
3、CCK-8法检测雷公藤红素耐药逆转性
取对数生长期、存活率大于95%的K562/A02细胞(2～3×104cells/孔)于96孔板中。实验分组：①K562/A02、②K562/A02+雷公藤红素、③K562/A02+VLP。所加ADM等药物浓度同上,每孔设3个平行孔,终体积150μl。并用维拉帕米(VLP)组5μg/L作为阳性对照。在37℃,5%CO2培养箱中孵育72小时后加入10μl CCK-8,继续培养2小时后,以空白孔调零,检测波长同上。计算半数抑制率(IC50)。实验重复3次。逆转倍数=(耐药细胞逆转前的IC50/耐药细胞逆转后的IC50)。
4、流式细胞术检测K562和K562/A02细胞内的ADM浓度
取对数生长期、存活率大于95%的细胞于24孔板中,实验分6组①K562/A02、②K562/A02+ADM、③K562/A02+ADM+雷公藤红素(IC50)、④K562/A02+ADM+雷公藤红素(IC50)、⑤K562、⑥K562+ADM。第③、④组分别先加入IC10和IC50的雷公藤红素,24h后在第②③④⑥组中再加入ADM10μg/ml,药物作用3小时,收集细胞1×106个细胞,冷PBS(4℃,0.01mol/L,Ph7.4)洗涤2次,再重悬于冷PBS液中,4℃保存至上样进行流式细胞仪检测(激发波长Ex=488nm,发射波长Em=575nm)。
5、流式细胞术检测P-gp表达
取对数生长期、存活率大于95%的细胞于24孔板中,实验分4组,分别为①K562/A02、②K562/A02+ADM(IC50)、③K562/A02+雷公藤红素(IC50)、④K562/A02+ADM(IC50)+雷公藤红素(IC50),置培养箱孵育48h后,收集细胞,约3×105个细胞,用冷的PBS液洗2遍,按操作说明加入P-gp抗体,室温下避光孵育30分钟后上流式细胞仪检测,并给出相应的P-gp表达率。
结果：
1、雷公藤红素对K562、K562/A02细胞的增值抑制作用结果
雷公藤红素对K562和K562/A02细胞的IC50分别为411.59±26.551μmol/L和295.58±23.288μmol/L,两者差异明显(P<0.05)。ADM对K562、K562/A02的IC50分别为0.749±0.741μmol/L、59.755±6.883μmol/L,耐药倍数为79.78倍,说明K562/A02对ADM有明显的耐药性(P<0.05)。细胞毒剂量的雷公藤红素可降低ADM对K562/A02细胞的IC50,提高对ADM的敏感性,应用雷公藤红素后,IC50为0.507±0.070μmol/L,较单用ADM明显减低(P<0.05),耐药性逆转倍数(RF)为117.860倍；而加入5μg/L维拉帕米后的IC50为17.196±6.303μmol/L,也明显低于单用ADM组(P<0.05),RF为3.745倍。
2、流式细胞仪检测细胞内阿霉素浓度和细胞膜P-gp的表达结果
经流式细胞仪检测发现加入雷公藤红素后,细胞内的ADM的浓度明显增加,加入IC,。浓度的雷公藤红素和IC50浓度的雷公藤红素后细胞内的阿霉素浓度分别为73.727±8.626、102.86±4.518；增加倍数分别为1.102和1.537倍。且两组细胞内的阿霉素浓度有明显差异(P<0.05)。单用阿霉素时,K562/A02细胞的P-gp的表达波峰无明显影响；单用雷公藤红素后,K652/A02细胞的P-gp的表达波峰明显降低；当雷公藤红素和阿霉素合用后,K562/A02细胞的P-gp的表达也比单用阿霉素有明显的降低。
结论：
1、阿霉素和雷公藤红素对K562/A02、K562的半数抑制率浓度(IC50)均有显著差异。K562/A02细胞对ADM的耐药性是K562细胞的79.78倍。
2、细胞毒剂量的雷公藤红素作用后,ADM对K562/A02细胞的IC50显著下降。
3、细胞毒剂量和非细胞毒剂量的雷公藤红素处理后的K562/A02细胞和K562细胞内的ADM浓度显著增加。
4、雷公藤红素能明显下调K562/A02细胞的P-gp表达。
Leukemia is one of the most common malignant tumor in beings,which is a heterogeneous group of clonal origins of malignant disease. The incidence of leukemia is reported to be 3-4/100,000 per year. The main treatment method for leukemia is dependent on chemotherapy. With the development of chemotherapy plans and the apperence of new medicines, supportive care and stem cell transplantation to enhance the application of the treatment of leukemia has been significantly improved. However, the emergence of mulyidrug resistance is not become part of the leukemia patients in remission, or the main reason for relapse after remission. Therefore, the searching for new anticancer drugs, and exploring new treatment options is of great significant.
In recent years, some of traditional Chinese medicine and its active ingredient reversal of multidrug resistance of leukemia caused people's attentions. Celastrol or Tripterygium, one of traditional Chinese medicines, is belonging to Wilfordil hook and celastrol is one of the monomers of tripterygium. Chemically, Celastrol belongs to triterpene constituents with molecular weight 450 and its molecular formula is C29H3gO4.It reported that tripterine inhibite immune; inhibition of vascular endothelial cells in vitro value;inhibition of HMC-1 cells adhesion and adhesion molecule expression; Celastrol also induced apoptosis of tumor such as non-small cell lung cancer line H1299,human acute myeloid leukemia cell line HL-60,malignant glioma lines and retinoblastoma.
In this study, we use human chronic myelogenous leukemia blast crisis cell lines K562 and K562/A02 cell line resistance to adrimycin as the target cell to determine the reverse effect of Tripterine by CCK-8 and flow cytometry,and detected the concentration of intracellular ADM and P-gp expression by Tripterine.
Materials and Method
1、Culture of K562 and K562/A02
K562 cells were cultured with 10% newborn calf serum RPMI-1640 medium, which include in 100U/mL,100μg/mL penicillin and streptomycin per liter.K562/A02 cells were cultured with the same medium, but this medium add adriamycin(ADM1μmol/L).The two kinds of cells were cultured at 37℃,5%CO2 incubator in noemal culture. Every 2 to 3 days passage 1 times. K562/A02 cells changed with adriamycin-free medium two weeks before experiment. Logarithmic growth phase cells were used for experiments.
2、The sensitivity of cells to ADM or Celastrol and the reversal of drug resistance were determined with CCK-8method.
Logarithmic growth phase cells were used for experiments. Living cell counting methed based on Trypan bluedye staining staining was used for tumor cell killing test. Take 20μL cell suspension with the examinated under microscope to count 100 cells for calculating living cell persatages. Trypan bluedye stained cells deal and non-stained cells means living. Take activity greater than 95% of cells for experimental cell. K562 or K562/A02 cells of 2～3×109cells per well were inoculated into 96- well. High to low concentrations of ADM were added(such as 160、80、40、20、10、5、2.5、1.25μmol/L).The same method with Celastrol (such as 320、160、80、40、20、10、5、2.5μmol/L).Each bore hole had three repetitive wells. The volume of every wells was 150μl. The cells cultured in 37℃,5%CO2 incubator after 72 hours, each well by adding 10μl CCK-8 reagent. Continued to train 2 hours.
Zero with an empty hole, put the 96-well in automatic microplate reader at absorbance measured at 450nm,and the reference wavelength of 650nm. The measured data using statistical software to calculate SPSS16.0.The SPSS 16.0 software could calculate the growth inhibition rate of 50% of the drug concentration that is half inhibition(IC50).The inhibition was calculated as follows:Inhibition=(1-Experimental group's OD)/Control group's OD);Resistance index=IC50 of K562/A02/IC50 of K562.The experiment was repeated three times and averaged the datas.
3、The drug resistance of Celastrol were determined with CCK-8.
Logarithmic growth phase K562/A02 cells, which activity greater than 95%. K562/A02 cells of 2～3×109cells per well were inoculated into 96- well. The experiment groups divided into the following groups:①K562/A02;②K562/A02+ Celastrol;③K562/A02+VLP.The concentration of ADM and other drugs as discussed earlier. Each bore hole had three repetitive wells. The volume of every wells was 150μL. The VLP(5μg/L) as positive control. The cells cultured in 37℃,5%CO2 incubator after 72 hours, each well by adding 10μl CCK-8 reagent. Continued to train 2 hours. Zero with an empty hole, and the detection wavelength as discussed earlier. The experiment was repeated three times. The reversal fold was calculated as follows: Reversal fold= The IC50 of before reversal of K562/A02/The IC50 of after reversal of K562/A02.
4、The intracellular of ADM concentration of K562/A02 and K562 by Flow cytometry.
Logarithmic growth phase K562/A02 and K562 cells inoculated into 24- well, which activity greater than 95%. The experiment groups divided into four groups:①K562/A02;②K562/A02+ADM(IC50);②K562/A02+ Celastrol (IC50);④K562/A02+ADM(IC50)+Celastrol (IC50). Following 48 hours in incubator, collected cells,washed with ice-cold PBS (4℃,0.01mol/L, Ph7.4) twice. Resuspended in ice-cold PBS.The samples were stored at 4℃first detected by flow cytometry.(Ex=488nm,Em=575nm)
5、P-gp expression detected by flow cytometry
Logarithmic growth phase K562/A02 cells inoculated into 24- well, which activity greater than 95%. The experiment groups divided into the following groups:①K562/A02;②K562/A02+ADM(IC50);③K562/A02+ Celastrol (IC50)④K562/A02+ADM(IC50)+ Celastrol (IC50). Following 48 hours in incubator, collected cells,washed with ice-cold PBS (4℃,0.01mol/L,Ph7.4) twice. Added the P-gp antibody following with the instruction. Used flow cytometry to detect the P-gp expression after incubated at room temperature away from light 30 min.
Result
1、The results of K562 and K562/A02 cells inhibition by Celastrol
The IC50 of Celastrol to K562/A02 and K562 cells were 295.58±23.288μmol/L、411.59±26.5511μmol/L.The results of two cells has a significant difference (P<0.05). This result explain that Celastrol has non-drug resistance in K562/A02 cells. The IC50 of ADM to K562/A02 and K562 cells were 59.755±6.883μmol/L、0.749±0.741μmol/L. The resistance of K562/A02 cells to ADM was 79.78 times of K562 cells. It explained that ADM has evident drug resistance in K562/A02. The cytotoxic does of Celastrol could reduce the IC50 of ADM in K562/A02. This cytotoxic does could increase the ADM's sensitivity. After incubating with cytotoxic does of Celastrol, the IC50 of ADM was 0.507±0.070μmol/L,which decreased significantly than only used ADM (P<0.05), and the resistance was reversed by 117.860 times. And the IC50 of VLP(5μg/L)was 17.196±6.303μmol/L,which decreased significantly than only used ADM too(P<0.05).The resistance was reversed by 3.745 times.
2、The results from concentration of intracellular ADM and P-gp expression were tested with flow cytometry (FCM)
Tested with Celastrol, the concentration of intracellular ADM included obviously. After incubation of cytotoxic and non-cytotoxic does of Celastrol, the intracellular concentration of ADM were73.727±8.626、102.86±4.518.It increased 1.537 and 1.102 times in K562/A02 and K562 cells(P<0.05).When used ADM alone, the crest of P-gp expression has not obvious change. When used Celastrol alone, the crest of P-gp expression has obviously lower. And when Celastrol with ADM, the crest of P-gp expression lower obviously than ADM.
Conclusion
1. The IC50 of Tripterine to K562/A02 and K562 cells had a significant difference. The resistance of K562/A02 cells to ADM was 79.78 times of K562 cells.
2. After incubating with cytotoxic does of Celastrol, the IC50 of ADM was obviously lower.
3. After incubation of cytotoxic and non-cytotoxic does of Celastrol, the intracellular concentration of ADM increased obviously.
4. Celastrol could down-regulate P-gp expression obviously.
近年来,中药及其有效的成分逆转白血病多药耐药引起了人们的注意。雷公藤泛指卫矛科雷公藤属植物,是我国传统的中药材。雷公藤红素是雷公藤单体之一,是一种三萜类天然化合物,又名南蛇藤素,分子式为C29H38O4。,分子量为450。文献报道雷公藤红素有免疫抑制、抑制血管内皮细胞体外增值、抑制HMC-1细胞的黏附及其黏附分子的表达；雷公藤红素还能体外诱导非小细胞肺癌细胞株H1299、人急性髓系白血病细胞株HL-60、恶性胶质细胞瘤株、视网膜母细胞瘤等肿瘤的凋亡。本研究以人慢性粒细胞白血病急变K562细胞株和耐阿霉素K562/A02细胞株为靶细胞,采用CCK-8方法和流式细胞术,探讨雷公藤红素对K562/A02细胞的逆转作用,并检测了雷公藤红素对K562/A02细胞内ADM浓度和P-gp的表达的影响。
方法：
1、K562和K562/A02细胞的培养
K562细胞培养于含10%新生牛血清、100U/ml青霉素和1000ug/ml链霉素的RPMI-1640培养基中,K562/A02细胞培养于含阿霉素(ADM 1μmol/L)的上述培养基中,将2种细胞置于37℃、5%CO2培养箱中常规培养,2-3天传代1次,其中K562/A02细胞在实验前两周改用无阿霉素的培养基培养。取对数生长期细胞用于实验。
2、CCK-8法检测ADM、雷公藤红素的细胞毒性及耐药细胞的耐药倍数
取对数生长期细胞,采用台盼兰染色活细胞计数方法。取30 u 1细胞悬液,用台盼兰染色后镜检100个细胞并计算活细胞百分率,其中拒染细胞为活细胞,染成蓝色的细胞为死细胞。取存活率大于95%的细胞为实验细胞。将K562和K562/A02细胞(2～3×109cells/孔)于96孔板中,由高到低浓度分别加入ADM(160、80、40、20、10、5、2.5、1.25μmol/L),雷公藤红素(320、160、80、40、20、10、5、2.5μmol/L),每孔设3个复孔,终体积150 u l。在37℃、5%CO2培养箱中培养72小时后,每孔加入CCK-8试剂10μ1,继续培养2小时,以空白孔调零,在全自动酶标仪450nm处测吸光度值,参比波长650nm。所测数据采用SPSS16.0统计软件计算生长抑制率在50%的药物浓度即半数抑制率(IC50)。抑制率(%)=(1-实验组0D值/对照组OD值)×100%；耐药倍数=(耐药细胞的IC50/敏感细胞的IC50)。实验重复3次,取平均值。
3、CCK-8法检测雷公藤红素耐药逆转性
取对数生长期、存活率大于95%的K562/A02细胞(2～3×104cells/孔)于96孔板中。实验分组：①K562/A02、②K562/A02+雷公藤红素、③K562/A02+VLP。所加ADM等药物浓度同上,每孔设3个平行孔,终体积150μl。并用维拉帕米(VLP)组5μg/L作为阳性对照。在37℃,5%CO2培养箱中孵育72小时后加入10μl CCK-8,继续培养2小时后,以空白孔调零,检测波长同上。计算半数抑制率(IC50)。实验重复3次。逆转倍数=(耐药细胞逆转前的IC50/耐药细胞逆转后的IC50)。
4、流式细胞术检测K562和K562/A02细胞内的ADM浓度
取对数生长期、存活率大于95%的细胞于24孔板中,实验分6组①K562/A02、②K562/A02+ADM、③K562/A02+ADM+雷公藤红素(IC50)、④K562/A02+ADM+雷公藤红素(IC50)、⑤K562、⑥K562+ADM。第③、④组分别先加入IC10和IC50的雷公藤红素,24h后在第②③④⑥组中再加入ADM10μg/ml,药物作用3小时,收集细胞1×106个细胞,冷PBS(4℃,0.01mol/L,Ph7.4)洗涤2次,再重悬于冷PBS液中,4℃保存至上样进行流式细胞仪检测(激发波长Ex=488nm,发射波长Em=575nm)。
5、流式细胞术检测P-gp表达
取对数生长期、存活率大于95%的细胞于24孔板中,实验分4组,分别为①K562/A02、②K562/A02+ADM(IC50)、③K562/A02+雷公藤红素(IC50)、④K562/A02+ADM(IC50)+雷公藤红素(IC50),置培养箱孵育48h后,收集细胞,约3×105个细胞,用冷的PBS液洗2遍,按操作说明加入P-gp抗体,室温下避光孵育30分钟后上流式细胞仪检测,并给出相应的P-gp表达率。
结果：
1、雷公藤红素对K562、K562/A02细胞的增值抑制作用结果
雷公藤红素对K562和K562/A02细胞的IC50分别为411.59±26.551μmol/L和295.58±23.288μmol/L,两者差异明显(P<0.05)。ADM对K562、K562/A02的IC50分别为0.749±0.741μmol/L、59.755±6.883μmol/L,耐药倍数为79.78倍,说明K562/A02对ADM有明显的耐药性(P<0.05)。细胞毒剂量的雷公藤红素可降低ADM对K562/A02细胞的IC50,提高对ADM的敏感性,应用雷公藤红素后,IC50为0.507±0.070μmol/L,较单用ADM明显减低(P<0.05),耐药性逆转倍数(RF)为117.860倍；而加入5μg/L维拉帕米后的IC50为17.196±6.303μmol/L,也明显低于单用ADM组(P<0.05),RF为3.745倍。
2、流式细胞仪检测细胞内阿霉素浓度和细胞膜P-gp的表达结果
经流式细胞仪检测发现加入雷公藤红素后,细胞内的ADM的浓度明显增加,加入IC,。浓度的雷公藤红素和IC50浓度的雷公藤红素后细胞内的阿霉素浓度分别为73.727±8.626、102.86±4.518；增加倍数分别为1.102和1.537倍。且两组细胞内的阿霉素浓度有明显差异(P<0.05)。单用阿霉素时,K562/A02细胞的P-gp的表达波峰无明显影响；单用雷公藤红素后,K652/A02细胞的P-gp的表达波峰明显降低；当雷公藤红素和阿霉素合用后,K562/A02细胞的P-gp的表达也比单用阿霉素有明显的降低。
结论：
1、阿霉素和雷公藤红素对K562/A02、K562的半数抑制率浓度(IC50)均有显著差异。K562/A02细胞对ADM的耐药性是K562细胞的79.78倍。
2、细胞毒剂量的雷公藤红素作用后,ADM对K562/A02细胞的IC50显著下降。
3、细胞毒剂量和非细胞毒剂量的雷公藤红素处理后的K562/A02细胞和K562细胞内的ADM浓度显著增加。
4、雷公藤红素能明显下调K562/A02细胞的P-gp表达。
Leukemia is one of the most common malignant tumor in beings,which is a heterogeneous group of clonal origins of malignant disease. The incidence of leukemia is reported to be 3-4/100,000 per year. The main treatment method for leukemia is dependent on chemotherapy. With the development of chemotherapy plans and the apperence of new medicines, supportive care and stem cell transplantation to enhance the application of the treatment of leukemia has been significantly improved. However, the emergence of mulyidrug resistance is not become part of the leukemia patients in remission, or the main reason for relapse after remission. Therefore, the searching for new anticancer drugs, and exploring new treatment options is of great significant.
In recent years, some of traditional Chinese medicine and its active ingredient reversal of multidrug resistance of leukemia caused people's attentions. Celastrol or Tripterygium, one of traditional Chinese medicines, is belonging to Wilfordil hook and celastrol is one of the monomers of tripterygium. Chemically, Celastrol belongs to triterpene constituents with molecular weight 450 and its molecular formula is C29H3gO4.It reported that tripterine inhibite immune; inhibition of vascular endothelial cells in vitro value;inhibition of HMC-1 cells adhesion and adhesion molecule expression; Celastrol also induced apoptosis of tumor such as non-small cell lung cancer line H1299,human acute myeloid leukemia cell line HL-60,malignant glioma lines and retinoblastoma.
In this study, we use human chronic myelogenous leukemia blast crisis cell lines K562 and K562/A02 cell line resistance to adrimycin as the target cell to determine the reverse effect of Tripterine by CCK-8 and flow cytometry,and detected the concentration of intracellular ADM and P-gp expression by Tripterine.
Materials and Method
1、Culture of K562 and K562/A02
K562 cells were cultured with 10% newborn calf serum RPMI-1640 medium, which include in 100U/mL,100μg/mL penicillin and streptomycin per liter.K562/A02 cells were cultured with the same medium, but this medium add adriamycin(ADM1μmol/L).The two kinds of cells were cultured at 37℃,5%CO2 incubator in noemal culture. Every 2 to 3 days passage 1 times. K562/A02 cells changed with adriamycin-free medium two weeks before experiment. Logarithmic growth phase cells were used for experiments.
2、The sensitivity of cells to ADM or Celastrol and the reversal of drug resistance were determined with CCK-8method.
Logarithmic growth phase cells were used for experiments. Living cell counting methed based on Trypan bluedye staining staining was used for tumor cell killing test. Take 20μL cell suspension with the examinated under microscope to count 100 cells for calculating living cell persatages. Trypan bluedye stained cells deal and non-stained cells means living. Take activity greater than 95% of cells for experimental cell. K562 or K562/A02 cells of 2～3×109cells per well were inoculated into 96- well. High to low concentrations of ADM were added(such as 160、80、40、20、10、5、2.5、1.25μmol/L).The same method with Celastrol (such as 320、160、80、40、20、10、5、2.5μmol/L).Each bore hole had three repetitive wells. The volume of every wells was 150μl. The cells cultured in 37℃,5%CO2 incubator after 72 hours, each well by adding 10μl CCK-8 reagent. Continued to train 2 hours.
Zero with an empty hole, put the 96-well in automatic microplate reader at absorbance measured at 450nm,and the reference wavelength of 650nm. The measured data using statistical software to calculate SPSS16.0.The SPSS 16.0 software could calculate the growth inhibition rate of 50% of the drug concentration that is half inhibition(IC50).The inhibition was calculated as follows:Inhibition=(1-Experimental group's OD)/Control group's OD);Resistance index=IC50 of K562/A02/IC50 of K562.The experiment was repeated three times and averaged the datas.
3、The drug resistance of Celastrol were determined with CCK-8.
Logarithmic growth phase K562/A02 cells, which activity greater than 95%. K562/A02 cells of 2～3×109cells per well were inoculated into 96- well. The experiment groups divided into the following groups:①K562/A02;②K562/A02+ Celastrol;③K562/A02+VLP.The concentration of ADM and other drugs as discussed earlier. Each bore hole had three repetitive wells. The volume of every wells was 150μL. The VLP(5μg/L) as positive control. The cells cultured in 37℃,5%CO2 incubator after 72 hours, each well by adding 10μl CCK-8 reagent. Continued to train 2 hours. Zero with an empty hole, and the detection wavelength as discussed earlier. The experiment was repeated three times. The reversal fold was calculated as follows: Reversal fold= The IC50 of before reversal of K562/A02/The IC50 of after reversal of K562/A02.
4、The intracellular of ADM concentration of K562/A02 and K562 by Flow cytometry.
Logarithmic growth phase K562/A02 and K562 cells inoculated into 24- well, which activity greater than 95%. The experiment groups divided into four groups:①K562/A02;②K562/A02+ADM(IC50);②K562/A02+ Celastrol (IC50);④K562/A02+ADM(IC50)+Celastrol (IC50). Following 48 hours in incubator, collected cells,washed with ice-cold PBS (4℃,0.01mol/L, Ph7.4) twice. Resuspended in ice-cold PBS.The samples were stored at 4℃first detected by flow cytometry.(Ex=488nm,Em=575nm)
5、P-gp expression detected by flow cytometry
Logarithmic growth phase K562/A02 cells inoculated into 24- well, which activity greater than 95%. The experiment groups divided into the following groups:①K562/A02;②K562/A02+ADM(IC50);③K562/A02+ Celastrol (IC50)④K562/A02+ADM(IC50)+ Celastrol (IC50). Following 48 hours in incubator, collected cells,washed with ice-cold PBS (4℃,0.01mol/L,Ph7.4) twice. Added the P-gp antibody following with the instruction. Used flow cytometry to detect the P-gp expression after incubated at room temperature away from light 30 min.
Result
1、The results of K562 and K562/A02 cells inhibition by Celastrol
The IC50 of Celastrol to K562/A02 and K562 cells were 295.58±23.288μmol/L、411.59±26.5511μmol/L.The results of two cells has a significant difference (P<0.05). This result explain that Celastrol has non-drug resistance in K562/A02 cells. The IC50 of ADM to K562/A02 and K562 cells were 59.755±6.883μmol/L、0.749±0.741μmol/L. The resistance of K562/A02 cells to ADM was 79.78 times of K562 cells. It explained that ADM has evident drug resistance in K562/A02. The cytotoxic does of Celastrol could reduce the IC50 of ADM in K562/A02. This cytotoxic does could increase the ADM's sensitivity. After incubating with cytotoxic does of Celastrol, the IC50 of ADM was 0.507±0.070μmol/L,which decreased significantly than only used ADM (P<0.05), and the resistance was reversed by 117.860 times. And the IC50 of VLP(5μg/L)was 17.196±6.303μmol/L,which decreased significantly than only used ADM too(P<0.05).The resistance was reversed by 3.745 times.
2、The results from concentration of intracellular ADM and P-gp expression were tested with flow cytometry (FCM)
Tested with Celastrol, the concentration of intracellular ADM included obviously. After incubation of cytotoxic and non-cytotoxic does of Celastrol, the intracellular concentration of ADM were73.727±8.626、102.86±4.518.It increased 1.537 and 1.102 times in K562/A02 and K562 cells(P<0.05).When used ADM alone, the crest of P-gp expression has not obvious change. When used Celastrol alone, the crest of P-gp expression has obviously lower. And when Celastrol with ADM, the crest of P-gp expression lower obviously than ADM.
Conclusion
1. The IC50 of Tripterine to K562/A02 and K562 cells had a significant difference. The resistance of K562/A02 cells to ADM was 79.78 times of K562 cells.
2. After incubating with cytotoxic does of Celastrol, the IC50 of ADM was obviously lower.
3. After incubation of cytotoxic and non-cytotoxic does of Celastrol, the intracellular concentration of ADM increased obviously.
4. Celastrol could down-regulate P-gp expression obviously.
引文
[1]李孟秋,窦洁,杜伟,等.雷公藤红素对小鼠的免疫抑制作用及其对IL-6mRNA表达影响的研究[J].中国临床药理学与治疗学,2008,13(2)：158-163.
[2]黄煜伦,周幽心,周岱,等.雷公藤红素抑制血管生成的实验研究[J].中华肿瘤杂志,2003,25(5)：429432.
[3]周幽心,孙成法,许期年,等.雷公藤红素抑制血管内皮细胞株增值的体外研究[J].实验癌症杂志,2004,19(6)：564-566.
[4]孙成法,周幽心,褚容涛,等.雷公藤红素对内皮细胞E-selectin和ICAM-1及CD31表达的实验研究[J].中国校医,2008,22(2)：127-129.
[5]陈国柱,徐元基,杜芝燕,等.雷公藤红素对非小细胞肺癌细胞株H1299增值与凋亡的影响[J].生物技术通讯,2008,6(19)：826-829.
[6]徐银海,严杰.雷公藤红素诱导人急性髓系白血病HL-60细胞凋亡及其机制的研究[J].浙江大学学报(理学版),2008,35(3)：311-314.
[7]周幽心,黄煜伦,许期年,等.雷公藤单体体外抑制胶质瘤细胞的实验研究[J].癌症,2002,21(10)：1106-1108.
[8]黄煜伦,周幽心,姜华,等.雷公藤红素抑制可移植性人脑胶质瘤生长相关分子[J].江苏医药,2007,33(1)：37-39.
[9]闵红波,黄勤,郭志勇,等.雷公藤红素诱导视网膜母细胞瘤Y79细胞凋亡及其对凋亡核因子-KB的影响[J].中国中医眼科杂志,2004,14(3)：146-148.
[10]Yang HJ,Chen D,Cui QZ,et al.Celastrol,a Triterpene Extracted form the Chinese"Thunder of God Vine,"Is a potent Proteasome inhibitor and Suppresses Human Prostate Cancer Growth in Nude Mice [J].Cancer Res,2006,66(9):4758-4765
[11]贾力.雷公藤属植物化学、药理和临床应用[J].药学通报.1985,20(2)：101
[12]国家医药管理局中草药情报中心站.植物药有效成分手册[M].北京：人民卫生出版社,1986,190.
[13]Kobayashi Y, Shen J, Li SH, et al. Suppressive effects of a plant-origin polyol, dulcitol on collgen-induced arthritis in mice[J].Nippon Yakurigaku Zasshi,1997,110(suppol):132-137.
[14]Chang FR, Hayashi K, Chen IH, et al. Antitumor agents.288.five new agarofurans[J]. Reissantia buchananii.J Nat Prod,2003,66(11):1416-1420.
[15]Ngassapa O, Soejarto DD, Pezzuto JM, et al. Quinone-methide triptertenes and salaspermic and from Koloona ochracea[J].J Nat Prod,1994,57(1):1-8.
[16]翟亚萍,张茵,马保根,等.雷公藤红素体外抑制人AML细胞的实验[J].白血病.淋巴瘤,2011,20(2)：76-78
[17]张罗修,余方考,郑秋影,等.雷公藤红素抑制抗体形成及抗炎作用[J].药学学报,1990,25(8)：573-577.
[18]刘瑞麟,刘忠令,李强,等.雷公藤红素抑制支气管哮喘小鼠气道炎症的实验研究[J]. 中华结核和呼吸杂志,2004,27(3)：165-168.
[19]周錾,吴叔明,陈晓宇,等.雷公藤红素对三硝基苯磺酸诱导的大鼠结肠炎的保护作用[J].胃肠病学,2007,12(3)：144-147.
[20]许晨,吴兆龙.雷公藤红素防治狼疮性肾炎肾小球硬化的研究[J].中国中西医结合肾病杂志,2002,3(3)：132-135.
[21]陈世壮,计磊,王玉萍,等.红素对大鼠肝脏内皮细胞的体外杀伤作用[J].前卫医药杂志,1999,16(6)：337-339.
[22]高勇,王杰军,梅长林,等.红素抑制血管生成实验研究[J].肿瘤,1998,18(4)：280-281.
[23]张丽娟,朱润庆,费雁,等.南蛇藤素对肿瘤血管的抑制作用[J].肿瘤防治研究,2005,32：(11)：719-720.
[24]Lotem J, Sachs 1.Control of apoptosis in hematopoiesis and leukemia by cytokines, tumor suppressor and oncogenes[J],Leukemia;1996,10(6):925-931.
[25]Oltvai ZN, Millman CL,Korsmeyer SJ, et al. Bcl-a heterodimerizes in vivo with a conserved homolog,Bax,that accelerates programmed cell death[J].Cell,1993,74(4):609-619.
[26]鲍一笑,余润泉,张灯海,等.雷公藤红素对人肥大细胞白血.病细胞系HMC-1作用的实验研究[J].中华血液学杂志,1999,20(3)：146-148.
[27]鲍一笑,张璐定,李莉,等.雷公藤红素对HMC-1细胞凋亡相关基因表达的影响[J].第二军医大学学报,2001,22(9)：833-835.
[28]鲍一笑,叶挺军,韩连书,等.雷公藤红素诱导人鼻息肉肥大细胞凋亡及机制[J].第军医大学学报,2000,21(2)：104-106.
[29]鲍一笑,张登海,张玲珍,等.雷公藤红素诱导CEM-6T细胞凋亡的机制研究[J].癌症,2002,21(10)：1106-1108.
[30]Lee JH, Koo TH, Yoon H, et al. Inhibition of NF-κB activation through targeting I kappa B kinase by celastrol, a quinine methide triterpenoid[J].Biochem Pharmacol,2006,72(10): 1311-1321.
[31]Sethi G, Ahn K S,Pandey M K, et al. Celostrol,a novel triterpene,potentiates TNF-induced apoptosis and suppresses invasion of tumor cells by inhibiting NF-kappa B-regulated gene product and TAK1-mediated NF-kappa B activation[J].Blood,2007,109(7):2727-2735.
[32]Chen G Z, Xu Y J, Du Z Y, et al. Role of Celastrol in Regulating Proliferation and Apoptosis of Non-small Cell Lung Cancer H1299 Cells [J]. Letters in Biotechnology,2008, 19(b):826-829.
[33]于韬,赵桂森,臧恒昌,等.肿瘤多药耐药逆转剂研究进展[J].中国药物化学杂志,2003；13：172-178
[34]Norgaard JM,Hokland P.Biology of multiple drug resistance in acute leukemia[J].Int J Hematol,2000,72:290-297.
[35]陈孝堂,陈筠.P糖蛋白介导的多药耐药及其逆转的研究进展[J].山西医药杂志,2007；11：1005-1007.
[36]Ruiz Gomez M J,Souviron Rodriguea A,Martinz Morillo M.P-glycoprotein, a membrane pump that represents a barrier to chemotherapy in cancer patients. An Med Interna,2002, 19(9):477
[37]Marzolini C,Paus E,Buclin T,et al. Polymophisms in human MDR1(P-glycoprotein):recent advances and clinical relevance. Clin Phamacol Ther,2004,75(1):13-33.
[38]Thiebaut F,Tsuruo T,Hamada H.Cellular localization of the multidrug resistance gene product P-glycoprotein in normal human tissue. Proc Natl Sci USA,1987;84:735-9
[39]刘玲,何玲,刘国卿.P-糖蛋白与细胞凋亡及肿瘤MDR的关系[J].药学进展,2005,29(3)：101-105.
[40]B Szachowicz-Petelska. Mechanisms of transport across cell mem-brances of complexes contained in antitumour drugs.International Journal of Pharmaceutics,2001,22(2):169-182.
[41]Penson RT.Oliva E, Skates SJ, et al. Expression of multidrug resistance-1 protein inversely correlates with palliate response and survival in ovarian cancer patients a study in serial samples[J].Gynecol Oncol,2004,93:98-106.
[42]周亭芳,庄英帜P53、P-gp蛋白在卵巢癌组织中的表达及意义[J].南华大学学报医学版.2009,37(4)：400-402
[43]Ying L,Anders H B, Puneeth I, et al. The Hyperglycemiainduced Inflammatory response in adipocytes[J].Biological Chemistry,2005,280:4617-4626.
[44]杜舟,黄萍,万丽等P-gp、TopoⅡ、GSTπ在胃癌中的表达及临床意义[J].浙江医学,2009,9,1226-1237
[45]韩杰,檀碧波,赵建辉,等.消化道肿瘤转移淋巴结中P糖蛋白和谷胱甘肽S转移酶π的表达与肿瘤化疗药物敏感性的关系[J].中华普通外科杂志,2009,24(7)：573-576
[46]李勇莉,李红军,张敏,等.胃癌淋巴结转移灶与原发灶P-糖蛋白的表达及意义[J].世界华人消化杂志,2008,16(21)：2404-2407
[47]Botti G,Chiappetta G,D'Aiuto G et al.PCNA/Cyclin and P-glycoprotein as prognostic factors in locally advanced breast cancer[J].An immunohistochemical, retrospective study:Tumori,1993,79:214.
[48]Koh EH,Chung HC,Lee KB,et al.The value of immunohistochemical detection of P-glycoprotein in breast cancer before and after induction chemotherapy[J].Yonsei Med J,1992,33:137
[49]Leith Cp. Frequency and clinical significance of the expression of the multidrug resistance proteins mdr1/P-glycoprotein,mrp1,and lrp in acute myeloid leukemia:a southwest oncology group syudy.Blood,1999,94:1086-1099.
[50]Drach D.Zhao S,Drach J.et al.Low incidence of MDR1 expression in acute promyelocytic leuckamemia[J].Br J Haematol,1995,90(2):369-374.
[51]Agostino Tafuri.MDRlprotein expression is an independent predictor of complete remission in newly diagnosed adult acute lymphoblastic leukemia. Blood 2002,100(3): 974-981.
[52]Alan F,List. Cyclosporine inhibition of P-glyeoprotein in chronic myeloid leukemia blast phase.Blood,2002,100(5):1910-1912.
[53]何海龙,王津媛,紫忆欢等,P糖蛋白表达在儿童急性白血病中的意义[J].中国小儿血液,2001；6(4)145-147.
[54]韩晓红.肿瘤细胞多药耐药逆转研究[J].北华大学学报(自然科学版),2005,2(6)：36-42
[1]Ling V.P-glycoprotein and resistance to anticancer drugs[J].Cancer,1992;60(6):2062-2066
[2]MAHADEVAN D, LIST A F.Targeting the multidrg resistance-transporter in AML:molecular regulation and therapeutie strategies[J].Blood,2004,104(7):1940-1951
[3]RUEFLI A A,SMYTH M J, JOHNSTONE R W. HMBA induce activation of a caspase-independent cell death pathway to overcome P-glycoprotein-mediated multidrug resistance[J].Blood,2000,95(7):2378-2385
[4]Lincke CR, Smit JJ, van der Vedel-Koerts T, et al.Strcture of the human MDR3 gene and physical mapping of the human MDR locus[J].J boil Chem,1991,266(8):1814-1819
[5]Kimura Y,Matsuo M,Takahashi K,et al.ATP hydrolysis-dependent multidrug effux transporter:MDR1/P-glycoprolein[J].Curr Drug Metab,2004,5(1):1-10.
[6]Robert J.Resistance to cytotoxic agents [J].Curr Opinpharmacol,2001,1(4):353-357
[7]Marzolini C,Paus E,Buclin T,et al. Polymophisms in human MDR1(P-glycoprotein):recent advances and clinical relevance. Clin Phamacol Ther,2004,75(1):13-33
[8]陈孝堂,陈筠.P糖蛋白介导的多药耐药及其逆转的研究进展[J].山西医药杂志,2007；11：1005-1007
[9]Marzolini C, Paus E, Buclin T, et al. Polymorphisma in human MDR1(P-glycoprotein):recent advances and clinical relevance[J].Clin Pharmacol Ther,2004,75(1):13-33
[10]Szabo D,Keyzer H,Kaiser HE,et al.Reversal of multidrug resistance of tumor cells [J].Anticancer Res,2000,20(6B):4261-4274
[11]B Szachowicz-Petelska. Mechanisms of transport across cell mem-brances of complexes contained in antitumour drugs.International Journal of Pharmaceutics,2001,22(2):169-182
[12]Tada Y, Wada M, Migita T, et al. Increased expression of multidrug resistance-associated proteins to doxorubicin[J].Int J Cancer,2002,98(4):630-635
[13]Lehne G.P-glycoprotein as a drug target in the treatment of multidrug resistance cancer[J].Curr Drug Targets 2000,1(1):85-89
[14]周亭芳,庄英帜.P53、P-gp蛋白在卵巢癌组织中的表达及意义[J].南华大学学报医学版.2009,37(4)：400-402
[15]Ying L,Anders H B, Puneeth I, et al. The Hyperglycemiainduced Inflammatory response in adipocytes[J].Biological Chemistry,2005,280:4617-4626
[16]杜舟,黄萍,万丽等.P-gp、TopoⅡ、 GSTπ在胃癌中的表达及临床意义[J].浙江医学,2009,9,1226-1237
[17]Botti G,Chiappetta G,D'Aiuto G et al.PCNA/Cyclin and P-glycoprotein as prognostic factors in locally advanced breast cancer[J].An immunohistochemical, retrospective study:Tumori,1993,79:214
[18]Koh EH,Chung HC,Lee KB,et al.The value of immunohistochemical detection of P-glycoprotein in breast cancer before and after induction chemotherapy[J].Yonsei Med J,1992,33:137
[19]何崇生,黄剑飞,朱惠君.膀胱多药耐药相关因子的表达及其临床研究[J].南通医学院学报,2004,24(1)：9-11
[20]黄剑飞,陈莉,施公胜.肝细胞癌中耐药相关基因的表达及其临床研究[J].河南肿瘤学杂志,2004,17(4)：235-237
[21]张艳梅,付红,姜影.P-糖蛋白在常见恶性肿瘤组织中表达的研究[J].肿瘤防治研究,2004,31(5)：276-277
[22]Leith Cp. Frequency and clinical significance of the expression of the multidrug resistance proteins mdrl/P-glycoprotein,mrpl,and lrp in acute myeloid leukemia:a southwest oncology group syudy.Blood,1999,94:1086-1099.
[23]Drach D.Zhao S,Drach J.et al.Low incidence of MDR1 expression in acute promyelocytic leuckamemia[J].Br J Haematol,1995,90(2):369-374
[24]Agostino Tafuri.MDRl protein expression is an independent predictor of complete remission in newly diagnosed adult acute lymphoblastic leukemia. Blood 2002,100(3):974-981
[25]Alan F,List. Cyclosporine inhibition of P-glyeoprotein in chronic myeloid leukemia blast phase.Blood,2002,100(5):1910-1912
[26]PLASSCHAERT SABINE L A, VELLENGA E, de BONT EVELINE S J M, et al. High functional P-glycoprotein actirity is more often present in T-cell acute lymphoblastic leukemia cells in adult than in children[J]. Leukemia,2003,44(1):85-95
[27]何海龙,王津媛,紫忆欢等,P糖蛋白表达在儿童急性白血病中的意义.中国小儿血液,2001：6(4)145-147
[28]Goasguen J E, Dossot J M, Fardel O, et al. Expression of the Multidrug Resistance-Associated P-Glycoprotein(P-170) in 59 Cases of De Novo Aucte Lymphoblastic Leukemia:Prognostic Implications[J].Blood,1993,9(1):2394-2398
[29]Zenkov AN, Sevortsova NV, Chernolovskaya EL, et al. Expression of the MDR1 genes in patients with lymphoma with primary bone maeeow involvement[J].Nucleosides Nucleotides Nucleic Acids,2004,23(6-7):843-847
[30]孙志伟,陈睿,孙英,等.P-糖蛋白在恶性淋巴瘤组织中的表达及意义[J].山东医药,2008,；48(48)：65-66
[31]潘启超,田晖.多种中药单体逆转肿瘤多药耐药性[J].科学通报,1995,40(20)：1901-1904
[32]陈宝安,苏爱玲,程坚等,汉防已甲素对白血病耐药细胞株K562/A02核因子κB表达的影响[J].中西医结合学报,2008,6(9)：956-956
[33]Xia W, Ao ZF, Zhu GR. An effective reversal agent of drug resistance in tumor cells-study on reversal of drug resistance by tetrandrine in leukemic cells. Nanjing Yi Ke Da Xue Bao.1995;15(3):543-546.Chinese with abstract in English
[34]Chio SU, Park SH, Kim KH et al. The bisbenzylisoquinoline alkaloids,tetrandine and fangchinoline, enhance the cytotoxicity of multidrug resistance-related drugs via modulation of P-glycoprotein[J].Anticancer Drugs,1998,9(3):255-261
[35]王天晓,杨晓红.功劳木中异汉防已碱对P-糖蛋白介导的人乳腺癌细胞多药耐药性的逆转作用[J].药学学报.2008,43(5)461-465
[36]蔡讯,陈芳源,韩洁英等.懈皮素恢复柔红霉素在白血病耐药细胞K562/ADM和HL-60/ADM中的分布[J].癌症,2004,23(12)：1611-1615
[37]靳英,周庚寅,张延国.植物多酚类化合物逆转肿瘤多药耐药的筛选.山东大学学报,2002,40(6)：497
[38]张晓丽,曹国宪,俞惠新,等.延胡索乙素逆转多药耐药性人乳腺癌细胞MCF-7[J].中药药理与临床,2005,21(6)：19-21
[39]常宏宇,潘凯丽,李琦等.姜黄素对K562/A02细胞上P-gp的表达及其功能的影响[J].细胞与分子免疫学杂志,2005,21(2)：240-242
[40]李燕.姜黄素体外逆转人胃癌细胞SGC7901/VCR多药耐药性[A].第四军医大学,2006
[41]贾莉,孔力,苗小艳等.蝎毒逆转K562/ADM细胞多药耐药性的初步研究[J].白血病.淋巴瘤,2002,11(2)：81-83
[42]胥雄阳,何松.苦参碱逆转人肝癌细胞株QGY/CDDP多药耐药性的实验研究[J].重庆医科大学学报,2008,33(4)：411-415
[43]王驰,陈鸿雁,舒艳等.氧化苦参碱对放疗鼻咽癌HNE-1细胞P-gp表达的影响[J].重庆医科大学学报,2005,30(1)：16-19
[44]Yang JS, Kok, LF. Lin YH, et al. Diallyl disulfide inhibits WEHI-31eukemia cells in vivo. Anticancer Res,2006;26(1A):219-225
[45]Arora A, Seth K,5hukla Y. Reversal of P-glycoprutein-mediated multidrug resistance by diallyl sulfide in K562 leukemic cells and in mouse live.Carcinogenesis,2004;25:941-949
[46]余敏,刘心,徐波等,大蒜素联合红霉素逆转K562/A02细胞多药耐药机理的研究[J].中国实验血液学杂志,2008,16(5)：1044-1049
[47]郝立宏,赵瑾瑶,杨佩满.川芎嗪与β-榄香烯联合应用对K562/ADM细胞的生长抑制作用[J].中华微生态学杂志,2002,14(5)：275
[48]宋娟,唐靖,何娟.川芎嗪对Caco-2细胞P-糖蛋白功能和表达的影响[J].中南药学,2007,5(5)：440
[49]王婷,双跃荣,庄小捷等.川芎嗪联合三氧化二绅逆转K562/ADM细胞多要耐药的实验研究[J].实用癌症杂志,2009,24(2)：121-124
[50]解霞,杨毅,高清波等.川芎嗪对人乳腺癌细胞MCF-7/ADM细胞多药耐药性的逆转及P-gp表达的影响[J].大连大学学报,2006,27(4)：76-78
[51]胡凯文,郑洪霞,齐静.浙贝母逆转白血病多药耐药的研究[J].中华血液学杂志,1999,20(12)：650-651
[52]胡凯文,陈信义,左明焕.浙贝母逆转白血病(肿瘤)细胞耐药的临床与实验研究[J].中国医药学报,2004,19(Z1)：15
[53]刘丽丽,刘艳娥,房国涛.三七总皂苷逆转乳腺癌细胞MCF-7/ADM多药耐药的实验研究[J].时珍国医国药.2008,19(4)：965-956
[54]Callaghan R,Crowley E,Potter S, et al. P-glycoprotein:so many ways to turn it on[J]. J Clin Pharmacol,2008,48(3):365
[55]Norimasa S, Tetsuro M, Tatsuto K, et al. Two dyridine analogues with more effective ability to reverse multidrug resistance and with lower calcium channel blocking activity than their dihydropyridine counterparts. Cancer Res,1990;50:3055-9
[56]Wilson WH, Jam DC, Brgant G, et al. Phase I and pharmacokinetic study of the multidrug resistance modulator dexverapamil with epoch chemotherapy, Clin Onco,1995,13(8):1985-1994
[57]杨仁池,卞寿庚,杨天楹.逆转白血病耐药性的研究进展[J].临床血液学杂志,1993,6(1)：16-18
[58]孔德晓,陈春燕,许复郁,等.米非司酮逆转K562/A02细胞多药耐药的研究[J].中华血液学杂志,2007,28(8)：555-559
[59]徐玉乔,惠延平,马世荣,等.环孢素A逆转人白血病耐药细胞系HL-60/ADM后氧自由基水平的变化[J].中国实验血液学杂志,2008；16(5)：1050-1054
[60]方圆.环孢素A逆转白血病多药耐药的临床探讨[J].中国肿瘤临床与康复,2005,12(1)：50-51
[61]Galski H, Lazarovici P, Gottesman MM, et al. KT-5270 reverses multidrug resistance in variant S49 mouse lymphoma cells transduced with the human mdr-1 cDNA and in human multidrug-resistant carcinoma cells. Eur J Cancer,1995,31:380-5
[62]Daruka Mahadevan Alan F. List. Targeting the multidrug resistance-transporter in AML: molecular regulation and therapeutic strategies.Blood,2004,104(7):1940-1951
[63]Yang HJ, Chen D, Cui QC, Celastrol,a Triterpene Extracted from the Chinese'Thunder of God Vine', Is a Potent Proteasome Inhibitor and Suppresses Human Prostate Cancer in Nude Mice[J].Cancer Res 2006;66:(9):4758-4765
[64]韩晓红.肿瘤细胞多药耐药逆转研究[J].北华大学学报(自然科学版),2005,2(6)：36-42
[65]高晓东,陈烨.雄黄对HL-60/ADR作用的初步研究[J].南通医学院学报,2001,21(4)：349-350
[66]汤涛,蒙凌华,陈凌际,等.鸦胆子油乳具有多药耐药逆转和拓扑异构酶Ⅱ抑制作用[J].中国药理学通报,2001,17(5)：534-539
[67]翟亚萍,张茵,马保根,等.雷公藤红素体外抑制人AML细胞的实验[J].白血病.淋巴瘤,2011,20(2)：76-78
[68]Oluwatuyi M,Kaata G W,Gibbons S. Antibacterial and resistance modifying activity of Rosmarinus officinalis.Phytochemistry,2004,65:3249-3254
[69]于晓宁,李颢,陈学良,等.鼠尾草酸逆转K562/A02细胞多药耐药的机制研究[J].中华血液学杂志,2010,30(6)：381-384
[70]罗伟,陈卫昌.雷公藤红素联合5-氟尿嘧啶在人结肠癌细胞中的相互作用[J].中国现代医药杂志,2008,10(12)：4-7
[71]陈进伟,骆蓉,张广森,等.K562/A02耐药细胞NF-κB活性测定及葛根素部分逆转耐药效应的初步研究[J].中华血液学杂志2006,27(7)：482-484
[72]陈宝安,盛茗,高峰,等.联合应用汉防已甲素和他莫西芬逆转K562/VCR细胞株式耐药.白血病.淋巴瘤,2001,10(2)：71-73
[73]陈宝安,单学赞,程坚,等.尼洛替尼联合5-溴汉防己甲素逆转K562/A02细胞耐药的研究[J].中华血液学杂志,2010,31(6)：385-388
[2]黄煜伦,周幽心,周岱,等.雷公藤红素抑制血管生成的实验研究[J].中华肿瘤杂志,2003,25(5)：429432.
[3]周幽心,孙成法,许期年,等.雷公藤红素抑制血管内皮细胞株增值的体外研究[J].实验癌症杂志,2004,19(6)：564-566.
[4]孙成法,周幽心,褚容涛,等.雷公藤红素对内皮细胞E-selectin和ICAM-1及CD31表达的实验研究[J].中国校医,2008,22(2)：127-129.
[5]陈国柱,徐元基,杜芝燕,等.雷公藤红素对非小细胞肺癌细胞株H1299增值与凋亡的影响[J].生物技术通讯,2008,6(19)：826-829.
[6]徐银海,严杰.雷公藤红素诱导人急性髓系白血病HL-60细胞凋亡及其机制的研究[J].浙江大学学报(理学版),2008,35(3)：311-314.
[7]周幽心,黄煜伦,许期年,等.雷公藤单体体外抑制胶质瘤细胞的实验研究[J].癌症,2002,21(10)：1106-1108.
[8]黄煜伦,周幽心,姜华,等.雷公藤红素抑制可移植性人脑胶质瘤生长相关分子[J].江苏医药,2007,33(1)：37-39.
[9]闵红波,黄勤,郭志勇,等.雷公藤红素诱导视网膜母细胞瘤Y79细胞凋亡及其对凋亡核因子-KB的影响[J].中国中医眼科杂志,2004,14(3)：146-148.
[10]Yang HJ,Chen D,Cui QZ,et al.Celastrol,a Triterpene Extracted form the Chinese"Thunder of God Vine,"Is a potent Proteasome inhibitor and Suppresses Human Prostate Cancer Growth in Nude Mice [J].Cancer Res,2006,66(9):4758-4765
[11]贾力.雷公藤属植物化学、药理和临床应用[J].药学通报.1985,20(2)：101
[12]国家医药管理局中草药情报中心站.植物药有效成分手册[M].北京：人民卫生出版社,1986,190.
[13]Kobayashi Y, Shen J, Li SH, et al. Suppressive effects of a plant-origin polyol, dulcitol on collgen-induced arthritis in mice[J].Nippon Yakurigaku Zasshi,1997,110(suppol):132-137.
[14]Chang FR, Hayashi K, Chen IH, et al. Antitumor agents.288.five new agarofurans[J]. Reissantia buchananii.J Nat Prod,2003,66(11):1416-1420.
[15]Ngassapa O, Soejarto DD, Pezzuto JM, et al. Quinone-methide triptertenes and salaspermic and from Koloona ochracea[J].J Nat Prod,1994,57(1):1-8.
[16]翟亚萍,张茵,马保根,等.雷公藤红素体外抑制人AML细胞的实验[J].白血病.淋巴瘤,2011,20(2)：76-78
[17]张罗修,余方考,郑秋影,等.雷公藤红素抑制抗体形成及抗炎作用[J].药学学报,1990,25(8)：573-577.
[18]刘瑞麟,刘忠令,李强,等.雷公藤红素抑制支气管哮喘小鼠气道炎症的实验研究[J]. 中华结核和呼吸杂志,2004,27(3)：165-168.
[19]周錾,吴叔明,陈晓宇,等.雷公藤红素对三硝基苯磺酸诱导的大鼠结肠炎的保护作用[J].胃肠病学,2007,12(3)：144-147.
[20]许晨,吴兆龙.雷公藤红素防治狼疮性肾炎肾小球硬化的研究[J].中国中西医结合肾病杂志,2002,3(3)：132-135.
[21]陈世壮,计磊,王玉萍,等.红素对大鼠肝脏内皮细胞的体外杀伤作用[J].前卫医药杂志,1999,16(6)：337-339.
[22]高勇,王杰军,梅长林,等.红素抑制血管生成实验研究[J].肿瘤,1998,18(4)：280-281.
[23]张丽娟,朱润庆,费雁,等.南蛇藤素对肿瘤血管的抑制作用[J].肿瘤防治研究,2005,32：(11)：719-720.
[24]Lotem J, Sachs 1.Control of apoptosis in hematopoiesis and leukemia by cytokines, tumor suppressor and oncogenes[J],Leukemia;1996,10(6):925-931.
[25]Oltvai ZN, Millman CL,Korsmeyer SJ, et al. Bcl-a heterodimerizes in vivo with a conserved homolog,Bax,that accelerates programmed cell death[J].Cell,1993,74(4):609-619.
[26]鲍一笑,余润泉,张灯海,等.雷公藤红素对人肥大细胞白血.病细胞系HMC-1作用的实验研究[J].中华血液学杂志,1999,20(3)：146-148.
[27]鲍一笑,张璐定,李莉,等.雷公藤红素对HMC-1细胞凋亡相关基因表达的影响[J].第二军医大学学报,2001,22(9)：833-835.
[28]鲍一笑,叶挺军,韩连书,等.雷公藤红素诱导人鼻息肉肥大细胞凋亡及机制[J].第军医大学学报,2000,21(2)：104-106.
[29]鲍一笑,张登海,张玲珍,等.雷公藤红素诱导CEM-6T细胞凋亡的机制研究[J].癌症,2002,21(10)：1106-1108.
[30]Lee JH, Koo TH, Yoon H, et al. Inhibition of NF-κB activation through targeting I kappa B kinase by celastrol, a quinine methide triterpenoid[J].Biochem Pharmacol,2006,72(10): 1311-1321.
[31]Sethi G, Ahn K S,Pandey M K, et al. Celostrol,a novel triterpene,potentiates TNF-induced apoptosis and suppresses invasion of tumor cells by inhibiting NF-kappa B-regulated gene product and TAK1-mediated NF-kappa B activation[J].Blood,2007,109(7):2727-2735.
[32]Chen G Z, Xu Y J, Du Z Y, et al. Role of Celastrol in Regulating Proliferation and Apoptosis of Non-small Cell Lung Cancer H1299 Cells [J]. Letters in Biotechnology,2008, 19(b):826-829.
[33]于韬,赵桂森,臧恒昌,等.肿瘤多药耐药逆转剂研究进展[J].中国药物化学杂志,2003；13：172-178
[34]Norgaard JM,Hokland P.Biology of multiple drug resistance in acute leukemia[J].Int J Hematol,2000,72:290-297.
[35]陈孝堂,陈筠.P糖蛋白介导的多药耐药及其逆转的研究进展[J].山西医药杂志,2007；11：1005-1007.
[36]Ruiz Gomez M J,Souviron Rodriguea A,Martinz Morillo M.P-glycoprotein, a membrane pump that represents a barrier to chemotherapy in cancer patients. An Med Interna,2002, 19(9):477
[37]Marzolini C,Paus E,Buclin T,et al. Polymophisms in human MDR1(P-glycoprotein):recent advances and clinical relevance. Clin Phamacol Ther,2004,75(1):13-33.
[38]Thiebaut F,Tsuruo T,Hamada H.Cellular localization of the multidrug resistance gene product P-glycoprotein in normal human tissue. Proc Natl Sci USA,1987;84:735-9
[39]刘玲,何玲,刘国卿.P-糖蛋白与细胞凋亡及肿瘤MDR的关系[J].药学进展,2005,29(3)：101-105.
[40]B Szachowicz-Petelska. Mechanisms of transport across cell mem-brances of complexes contained in antitumour drugs.International Journal of Pharmaceutics,2001,22(2):169-182.
[41]Penson RT.Oliva E, Skates SJ, et al. Expression of multidrug resistance-1 protein inversely correlates with palliate response and survival in ovarian cancer patients a study in serial samples[J].Gynecol Oncol,2004,93:98-106.
[42]周亭芳,庄英帜P53、P-gp蛋白在卵巢癌组织中的表达及意义[J].南华大学学报医学版.2009,37(4)：400-402
[43]Ying L,Anders H B, Puneeth I, et al. The Hyperglycemiainduced Inflammatory response in adipocytes[J].Biological Chemistry,2005,280:4617-4626.
[44]杜舟,黄萍,万丽等P-gp、TopoⅡ、GSTπ在胃癌中的表达及临床意义[J].浙江医学,2009,9,1226-1237
[45]韩杰,檀碧波,赵建辉,等.消化道肿瘤转移淋巴结中P糖蛋白和谷胱甘肽S转移酶π的表达与肿瘤化疗药物敏感性的关系[J].中华普通外科杂志,2009,24(7)：573-576
[46]李勇莉,李红军,张敏,等.胃癌淋巴结转移灶与原发灶P-糖蛋白的表达及意义[J].世界华人消化杂志,2008,16(21)：2404-2407
[47]Botti G,Chiappetta G,D'Aiuto G et al.PCNA/Cyclin and P-glycoprotein as prognostic factors in locally advanced breast cancer[J].An immunohistochemical, retrospective study:Tumori,1993,79:214.
[48]Koh EH,Chung HC,Lee KB,et al.The value of immunohistochemical detection of P-glycoprotein in breast cancer before and after induction chemotherapy[J].Yonsei Med J,1992,33:137
[49]Leith Cp. Frequency and clinical significance of the expression of the multidrug resistance proteins mdr1/P-glycoprotein,mrp1,and lrp in acute myeloid leukemia:a southwest oncology group syudy.Blood,1999,94:1086-1099.
[50]Drach D.Zhao S,Drach J.et al.Low incidence of MDR1 expression in acute promyelocytic leuckamemia[J].Br J Haematol,1995,90(2):369-374.
[51]Agostino Tafuri.MDRlprotein expression is an independent predictor of complete remission in newly diagnosed adult acute lymphoblastic leukemia. Blood 2002,100(3): 974-981.
[52]Alan F,List. Cyclosporine inhibition of P-glyeoprotein in chronic myeloid leukemia blast phase.Blood,2002,100(5):1910-1912.
[53]何海龙,王津媛,紫忆欢等,P糖蛋白表达在儿童急性白血病中的意义[J].中国小儿血液,2001；6(4)145-147.
[54]韩晓红.肿瘤细胞多药耐药逆转研究[J].北华大学学报(自然科学版),2005,2(6)：36-42
[1]Ling V.P-glycoprotein and resistance to anticancer drugs[J].Cancer,1992;60(6):2062-2066
[2]MAHADEVAN D, LIST A F.Targeting the multidrg resistance-transporter in AML:molecular regulation and therapeutie strategies[J].Blood,2004,104(7):1940-1951
[3]RUEFLI A A,SMYTH M J, JOHNSTONE R W. HMBA induce activation of a caspase-independent cell death pathway to overcome P-glycoprotein-mediated multidrug resistance[J].Blood,2000,95(7):2378-2385
[4]Lincke CR, Smit JJ, van der Vedel-Koerts T, et al.Strcture of the human MDR3 gene and physical mapping of the human MDR locus[J].J boil Chem,1991,266(8):1814-1819
[5]Kimura Y,Matsuo M,Takahashi K,et al.ATP hydrolysis-dependent multidrug effux transporter:MDR1/P-glycoprolein[J].Curr Drug Metab,2004,5(1):1-10.
[6]Robert J.Resistance to cytotoxic agents [J].Curr Opinpharmacol,2001,1(4):353-357
[7]Marzolini C,Paus E,Buclin T,et al. Polymophisms in human MDR1(P-glycoprotein):recent advances and clinical relevance. Clin Phamacol Ther,2004,75(1):13-33
[8]陈孝堂,陈筠.P糖蛋白介导的多药耐药及其逆转的研究进展[J].山西医药杂志,2007；11：1005-1007
[9]Marzolini C, Paus E, Buclin T, et al. Polymorphisma in human MDR1(P-glycoprotein):recent advances and clinical relevance[J].Clin Pharmacol Ther,2004,75(1):13-33
[10]Szabo D,Keyzer H,Kaiser HE,et al.Reversal of multidrug resistance of tumor cells [J].Anticancer Res,2000,20(6B):4261-4274
[11]B Szachowicz-Petelska. Mechanisms of transport across cell mem-brances of complexes contained in antitumour drugs.International Journal of Pharmaceutics,2001,22(2):169-182
[12]Tada Y, Wada M, Migita T, et al. Increased expression of multidrug resistance-associated proteins to doxorubicin[J].Int J Cancer,2002,98(4):630-635
[13]Lehne G.P-glycoprotein as a drug target in the treatment of multidrug resistance cancer[J].Curr Drug Targets 2000,1(1):85-89
[14]周亭芳,庄英帜.P53、P-gp蛋白在卵巢癌组织中的表达及意义[J].南华大学学报医学版.2009,37(4)：400-402
[15]Ying L,Anders H B, Puneeth I, et al. The Hyperglycemiainduced Inflammatory response in adipocytes[J].Biological Chemistry,2005,280:4617-4626
[16]杜舟,黄萍,万丽等.P-gp、TopoⅡ、 GSTπ在胃癌中的表达及临床意义[J].浙江医学,2009,9,1226-1237
[17]Botti G,Chiappetta G,D'Aiuto G et al.PCNA/Cyclin and P-glycoprotein as prognostic factors in locally advanced breast cancer[J].An immunohistochemical, retrospective study:Tumori,1993,79:214
[18]Koh EH,Chung HC,Lee KB,et al.The value of immunohistochemical detection of P-glycoprotein in breast cancer before and after induction chemotherapy[J].Yonsei Med J,1992,33:137
[19]何崇生,黄剑飞,朱惠君.膀胱多药耐药相关因子的表达及其临床研究[J].南通医学院学报,2004,24(1)：9-11
[20]黄剑飞,陈莉,施公胜.肝细胞癌中耐药相关基因的表达及其临床研究[J].河南肿瘤学杂志,2004,17(4)：235-237
[21]张艳梅,付红,姜影.P-糖蛋白在常见恶性肿瘤组织中表达的研究[J].肿瘤防治研究,2004,31(5)：276-277
[22]Leith Cp. Frequency and clinical significance of the expression of the multidrug resistance proteins mdrl/P-glycoprotein,mrpl,and lrp in acute myeloid leukemia:a southwest oncology group syudy.Blood,1999,94:1086-1099.
[23]Drach D.Zhao S,Drach J.et al.Low incidence of MDR1 expression in acute promyelocytic leuckamemia[J].Br J Haematol,1995,90(2):369-374
[24]Agostino Tafuri.MDRl protein expression is an independent predictor of complete remission in newly diagnosed adult acute lymphoblastic leukemia. Blood 2002,100(3):974-981
[25]Alan F,List. Cyclosporine inhibition of P-glyeoprotein in chronic myeloid leukemia blast phase.Blood,2002,100(5):1910-1912
[26]PLASSCHAERT SABINE L A, VELLENGA E, de BONT EVELINE S J M, et al. High functional P-glycoprotein actirity is more often present in T-cell acute lymphoblastic leukemia cells in adult than in children[J]. Leukemia,2003,44(1):85-95
[27]何海龙,王津媛,紫忆欢等,P糖蛋白表达在儿童急性白血病中的意义.中国小儿血液,2001：6(4)145-147
[28]Goasguen J E, Dossot J M, Fardel O, et al. Expression of the Multidrug Resistance-Associated P-Glycoprotein(P-170) in 59 Cases of De Novo Aucte Lymphoblastic Leukemia:Prognostic Implications[J].Blood,1993,9(1):2394-2398
[29]Zenkov AN, Sevortsova NV, Chernolovskaya EL, et al. Expression of the MDR1 genes in patients with lymphoma with primary bone maeeow involvement[J].Nucleosides Nucleotides Nucleic Acids,2004,23(6-7):843-847
[30]孙志伟,陈睿,孙英,等.P-糖蛋白在恶性淋巴瘤组织中的表达及意义[J].山东医药,2008,；48(48)：65-66
[31]潘启超,田晖.多种中药单体逆转肿瘤多药耐药性[J].科学通报,1995,40(20)：1901-1904
[32]陈宝安,苏爱玲,程坚等,汉防已甲素对白血病耐药细胞株K562/A02核因子κB表达的影响[J].中西医结合学报,2008,6(9)：956-956
[33]Xia W, Ao ZF, Zhu GR. An effective reversal agent of drug resistance in tumor cells-study on reversal of drug resistance by tetrandrine in leukemic cells. Nanjing Yi Ke Da Xue Bao.1995;15(3):543-546.Chinese with abstract in English
[34]Chio SU, Park SH, Kim KH et al. The bisbenzylisoquinoline alkaloids,tetrandine and fangchinoline, enhance the cytotoxicity of multidrug resistance-related drugs via modulation of P-glycoprotein[J].Anticancer Drugs,1998,9(3):255-261
[35]王天晓,杨晓红.功劳木中异汉防已碱对P-糖蛋白介导的人乳腺癌细胞多药耐药性的逆转作用[J].药学学报.2008,43(5)461-465
[36]蔡讯,陈芳源,韩洁英等.懈皮素恢复柔红霉素在白血病耐药细胞K562/ADM和HL-60/ADM中的分布[J].癌症,2004,23(12)：1611-1615
[37]靳英,周庚寅,张延国.植物多酚类化合物逆转肿瘤多药耐药的筛选.山东大学学报,2002,40(6)：497
[38]张晓丽,曹国宪,俞惠新,等.延胡索乙素逆转多药耐药性人乳腺癌细胞MCF-7[J].中药药理与临床,2005,21(6)：19-21
[39]常宏宇,潘凯丽,李琦等.姜黄素对K562/A02细胞上P-gp的表达及其功能的影响[J].细胞与分子免疫学杂志,2005,21(2)：240-242
[40]李燕.姜黄素体外逆转人胃癌细胞SGC7901/VCR多药耐药性[A].第四军医大学,2006
[41]贾莉,孔力,苗小艳等.蝎毒逆转K562/ADM细胞多药耐药性的初步研究[J].白血病.淋巴瘤,2002,11(2)：81-83
[42]胥雄阳,何松.苦参碱逆转人肝癌细胞株QGY/CDDP多药耐药性的实验研究[J].重庆医科大学学报,2008,33(4)：411-415
[43]王驰,陈鸿雁,舒艳等.氧化苦参碱对放疗鼻咽癌HNE-1细胞P-gp表达的影响[J].重庆医科大学学报,2005,30(1)：16-19
[44]Yang JS, Kok, LF. Lin YH, et al. Diallyl disulfide inhibits WEHI-31eukemia cells in vivo. Anticancer Res,2006;26(1A):219-225
[45]Arora A, Seth K,5hukla Y. Reversal of P-glycoprutein-mediated multidrug resistance by diallyl sulfide in K562 leukemic cells and in mouse live.Carcinogenesis,2004;25:941-949
[46]余敏,刘心,徐波等,大蒜素联合红霉素逆转K562/A02细胞多药耐药机理的研究[J].中国实验血液学杂志,2008,16(5)：1044-1049
[47]郝立宏,赵瑾瑶,杨佩满.川芎嗪与β-榄香烯联合应用对K562/ADM细胞的生长抑制作用[J].中华微生态学杂志,2002,14(5)：275
[48]宋娟,唐靖,何娟.川芎嗪对Caco-2细胞P-糖蛋白功能和表达的影响[J].中南药学,2007,5(5)：440
[49]王婷,双跃荣,庄小捷等.川芎嗪联合三氧化二绅逆转K562/ADM细胞多要耐药的实验研究[J].实用癌症杂志,2009,24(2)：121-124
[50]解霞,杨毅,高清波等.川芎嗪对人乳腺癌细胞MCF-7/ADM细胞多药耐药性的逆转及P-gp表达的影响[J].大连大学学报,2006,27(4)：76-78
[51]胡凯文,郑洪霞,齐静.浙贝母逆转白血病多药耐药的研究[J].中华血液学杂志,1999,20(12)：650-651
[52]胡凯文,陈信义,左明焕.浙贝母逆转白血病(肿瘤)细胞耐药的临床与实验研究[J].中国医药学报,2004,19(Z1)：15
[53]刘丽丽,刘艳娥,房国涛.三七总皂苷逆转乳腺癌细胞MCF-7/ADM多药耐药的实验研究[J].时珍国医国药.2008,19(4)：965-956
[54]Callaghan R,Crowley E,Potter S, et al. P-glycoprotein:so many ways to turn it on[J]. J Clin Pharmacol,2008,48(3):365
[55]Norimasa S, Tetsuro M, Tatsuto K, et al. Two dyridine analogues with more effective ability to reverse multidrug resistance and with lower calcium channel blocking activity than their dihydropyridine counterparts. Cancer Res,1990;50:3055-9
[56]Wilson WH, Jam DC, Brgant G, et al. Phase I and pharmacokinetic study of the multidrug resistance modulator dexverapamil with epoch chemotherapy, Clin Onco,1995,13(8):1985-1994
[57]杨仁池,卞寿庚,杨天楹.逆转白血病耐药性的研究进展[J].临床血液学杂志,1993,6(1)：16-18
[58]孔德晓,陈春燕,许复郁,等.米非司酮逆转K562/A02细胞多药耐药的研究[J].中华血液学杂志,2007,28(8)：555-559
[59]徐玉乔,惠延平,马世荣,等.环孢素A逆转人白血病耐药细胞系HL-60/ADM后氧自由基水平的变化[J].中国实验血液学杂志,2008；16(5)：1050-1054
[60]方圆.环孢素A逆转白血病多药耐药的临床探讨[J].中国肿瘤临床与康复,2005,12(1)：50-51
[61]Galski H, Lazarovici P, Gottesman MM, et al. KT-5270 reverses multidrug resistance in variant S49 mouse lymphoma cells transduced with the human mdr-1 cDNA and in human multidrug-resistant carcinoma cells. Eur J Cancer,1995,31:380-5
[62]Daruka Mahadevan Alan F. List. Targeting the multidrug resistance-transporter in AML: molecular regulation and therapeutic strategies.Blood,2004,104(7):1940-1951
[63]Yang HJ, Chen D, Cui QC, Celastrol,a Triterpene Extracted from the Chinese'Thunder of God Vine', Is a Potent Proteasome Inhibitor and Suppresses Human Prostate Cancer in Nude Mice[J].Cancer Res 2006;66:(9):4758-4765
[64]韩晓红.肿瘤细胞多药耐药逆转研究[J].北华大学学报(自然科学版),2005,2(6)：36-42
[65]高晓东,陈烨.雄黄对HL-60/ADR作用的初步研究[J].南通医学院学报,2001,21(4)：349-350
[66]汤涛,蒙凌华,陈凌际,等.鸦胆子油乳具有多药耐药逆转和拓扑异构酶Ⅱ抑制作用[J].中国药理学通报,2001,17(5)：534-539
[67]翟亚萍,张茵,马保根,等.雷公藤红素体外抑制人AML细胞的实验[J].白血病.淋巴瘤,2011,20(2)：76-78
[68]Oluwatuyi M,Kaata G W,Gibbons S. Antibacterial and resistance modifying activity of Rosmarinus officinalis.Phytochemistry,2004,65:3249-3254
[69]于晓宁,李颢,陈学良,等.鼠尾草酸逆转K562/A02细胞多药耐药的机制研究[J].中华血液学杂志,2010,30(6)：381-384
[70]罗伟,陈卫昌.雷公藤红素联合5-氟尿嘧啶在人结肠癌细胞中的相互作用[J].中国现代医药杂志,2008,10(12)：4-7
[71]陈进伟,骆蓉,张广森,等.K562/A02耐药细胞NF-κB活性测定及葛根素部分逆转耐药效应的初步研究[J].中华血液学杂志2006,27(7)：482-484
[72]陈宝安,盛茗,高峰,等.联合应用汉防已甲素和他莫西芬逆转K562/VCR细胞株式耐药.白血病.淋巴瘤,2001,10(2)：71-73
[73]陈宝安,单学赞,程坚,等.尼洛替尼联合5-溴汉防己甲素逆转K562/A02细胞耐药的研究[J].中华血液学杂志,2010,31(6)：385-388